登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600981证券简称：苏豪汇鸿 公告编号：2025-079 江苏苏豪汇鸿集团股份有限公司 关于部分资产置换关联交易暨 增加年度投资计划并实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 江苏苏豪汇鸿集团股份有限公司（以下简称"公司"）拟与控股股东江苏省苏豪控股集团有限公司（以 下简称"苏豪控股"）进行资产置换。本次交易拟完成苏豪控股直接和通过其全资子公司江苏苏豪亚欧互 联科技集团有限公司（以下简称"亚欧互联"）间接持有的紫金财产保险股份有限公司（以下简称"紫金 财险"）合计2.33%股权（14,000万份股份）置入公司。 ● 本次交易构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 ● 交易作价及支付：本次交易价格以经国资备案的资产评估报告的评估结果为依据。根据北方亚事资产 评估有限责任公司出具的评估报告，截至评估基准日2024年12月31日，紫金财险2.33%股权（14,000万 份股份）评估价值为26,161. ...

Market Overview - The three major indices in the Shanghai and Shenzhen markets showed mixed performance, with total trading volume decreasing to 1.56 trillion yuan [1][7] - The ADP employment report for November indicated a decrease of 32,000 jobs, marking the largest decline in two and a half years, which was significantly below the expected increase of 10,000 jobs [2][8] - The probability of the Federal Reserve cutting interest rates by 25 basis points in December is close to 90%, as indicated by CME's FedWatch tool, further reinforcing market expectations for a dovish stance [2][8] Policy Developments - The State-owned Assets Supervision and Administration Commission (SASAC) held a meeting to promote value creation actions among state-owned enterprises, emphasizing the importance of strategic safety, industry leadership, and comprehensive support [2][3][9] - The approval of the Yangtze River Delta Spatial Planning (2023-2035) marks a new phase in regional integration, focusing on urban agglomeration and enhancing Shanghai's leading role [3][9] Market Performance - As of December 4, the Shanghai Composite Index closed at 3,875.79 points, down 0.06%, while the Shenzhen Component Index rose by 0.40% to 13,006.72 points, and the ChiNext Index increased by 1.01% to 3,067.48 points [4][10] - The market saw 1,446 stocks rise and 3,667 stocks fall, indicating a challenging environment for many equities [10] Capital Flow - The market turnover was reported at 15,617.68 billion yuan, showing a decline compared to the previous trading day [5][11] - The margin trading balance was recorded at 24,825.92 billion yuan, also down from the previous day [11]

来源：新浪证券-红岸工作室 12月4日，四川黄金跌2.46%，成交额3.06亿元，换手率3.89%，总市值113.02亿元。 异动分析 黄金概念+西部大开发+国企改革 1、公司主要从事金矿的采选及销售。公司的主要产品为金精矿、合质金。经过多年发展，公司已成为 国内主要的金矿采选企业之一，系中国黄金协会理事单位，被评为国家级绿色矿山企业、四川省重点黄 金生产企业。 2、公司注册地址为四川省凉山彝族自治州木里藏族自治县乔瓦镇龙钦街26号 3、公司属于国有企业。公司的最终控制人为四川省地质矿产勘查开发局。 今日主力净流入-4019.96万，占比0.14%，行业排名6/11，连续3日被主力资金减仓；所属行业主力净流 入-4.47亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-4277.36万-6351.17万-3499.17万802.96万-7751.74万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.34亿，占总成交额的5.84%。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 截至9月30日，四川黄金股东户数3.59万，较上期 ...

（注：此文属于央广网登载的商业信息，文章内容不代表本网观点，仅供参考） 现代化生产（江苏银宝集团供图） 向内挖潜、提升管理效能是改革的重要一环。银宝盐业通过建立"五集中"管控体系，实施筑包生产线前移，有效降低了中转成本；清理冗余用工，累计节 约费用340余万元。公司深化"三项制度"改革，全面推行经理层任期制与契约化管理，畅通人才"双向流动"通道。在推进改革的同时，公司始终严守安全 环保底线，保持了安全生产"零事故"的良好记录。 银宝盐业公司党委书记、董事长王传华表示，"改革没有终点。下一步，我们将持续加大数字化建设投入，不断完善营销网络，以敢'闯'的精神、实'干'的 作风，持续增强转型发展内生动力，为集团高质量发展贡献更多'盐'值担当。" 国企改革是激活发展动能的关键抓手。近年来，江苏银宝集团盐业公司积极响应盐城市委、市政府关于国企改革深化提升的决策部署，紧密围绕"做足盐 文章"的战略定位，从产业布局优化、科技创新驱动到治理效能提升等多个维度协同发力，以改革为笔，奋力书写传统盐业向现代化转型的崭新答卷。 成片的盐田（江苏银宝集团供图） 在产业布局方面，银宝盐业持续夯实主业根基。东昇制盐公司20万吨日晒盐技改项 ...

Core Viewpoint - The Chinese rare earth market experienced a decline of 2.30% on December 4, with a trading volume of 1.199 billion yuan and a market capitalization of 48.699 billion yuan [1] Company Overview - The company primarily engages in the production and operation of rare earth oxides and provides rare earth technology research and consulting services [2][8] - The main products include high-purity rare earth oxides, with over 80% of products having a purity greater than 99.99%, and some reaching 99.9999% [2] - The company is controlled by the State-owned Assets Supervision and Administration Commission of the State Council, categorizing it as a state-owned enterprise [3][4] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.494 billion yuan, representing a year-on-year growth of 27.73%, and a net profit attributable to shareholders of 192 million yuan, up 194.67% year-on-year [8] - The company has distributed a total of 346 million yuan in dividends since its A-share listing, with 124 million yuan distributed in the last three years [9] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and several ETFs, indicating a diverse shareholder base [10] - The number of shareholders increased to 254,200, with an average of 4,174 shares per person, reflecting a slight decrease of 2.09% [8]

面对每晚海量的公告无从下手？《公告臻选》助你高效决策！专业筛选每晚最重要的关键公告，提供通 俗易懂的深度解读，揭示复杂术语背后的投资机会。助你10分钟掌握市场全貌，决胜开盘之前。 ①多肽药+创新药+原料药+减肥药！公司五肽-18通过药监局化妆品新原料备案；②一带一路+海外 基地优势+液体黄金"技术！公司拟投资1.5亿美元建设柬埔寨项目；③区域基建龙头+国企改革+新 型城镇化+重庆本地股，公司中标近30亿元工程项目。 前言 点击解锁付费内容，捕捉每天公告中的"黄金机会"！ ...

Core Viewpoint - Postal Savings Bank of China (PSBC) has experienced a decline in stock price and trading volume, indicating potential investor concerns and market dynamics [1][3]. Financial Performance - For the first nine months of 2025, PSBC reported a net profit of 765.62 billion yuan, reflecting a year-on-year growth of 0.98% [6]. - The bank's cumulative cash dividends since its A-share listing amount to 1,377.96 billion yuan, with 773.95 billion yuan distributed over the past three years [7]. Dividend and Shareholder Information - PSBC's dividend yields over the past three years were 5.58%, 6.00%, and 4.61% respectively, indicating a strong commitment to returning value to shareholders [2]. - As of September 30, 2025, the number of shareholders decreased by 13.09% to 142,600, while the average circulating shares per person increased by 15.29% to 478,570 shares [6]. Market Activity - On December 3, PSBC's stock fell by 1.23%, with a trading volume of 9.67 billion yuan and a turnover rate of 0.26%, leading to a total market capitalization of 6,725.32 billion yuan [1]. - The main capital flow showed a net outflow of 1.59 billion yuan today, with a continuous reduction in main capital over the past three days [3]. Technical Analysis - The average trading cost of PSBC shares is 5.18 yuan, with the current stock price fluctuating between resistance at 5.61 yuan and support at 5.59 yuan, suggesting potential for short-term trading strategies [4]. Company Overview - PSBC, established on March 6, 2007, and listed on December 10, 2019, primarily offers banking and financial services in China, with personal banking contributing 65.15% to its revenue, corporate banking 22.71%, and funding operations 12.10% [5].

5、子公司重庆市渝物民用爆破器材有限公司，主要经营炸药、雷管、导火索、导爆索等民用爆破器材 及原材料。 来源：新浪证券-红岸工作室 12月3日，重庆港涨1.55%，成交额5856.69万元，换手率0.95%，总市值62.31亿元。 异动分析 航运概念+统一大市场+国企改革+一带一路+民爆概念 1、公司主营业务是港口中转运输业务和综合物流业务，公司的主要产品及服务为装卸及客货代理业 务、综合物流业务、商品贸易业务、爆破施工业务。公司港口码头通过能力强。近年来通过对港口码头 建设投资及改(扩)建,已基本形成了集装箱、件杂散货、商品车和化工等专业化码头(群),港口货物通过能 力和集装箱吞吐能力位居西南地区首位。 2、公司以港口为依托，围绕铁、公、水多式联运，坚持大客户战略，充分整合仓储、航运、铁路、公 路、口岸等物流要素资源，积极拓展贸易物流、供应链物流等业务。 3、公司属于国有企业。公司的最终控制人为重庆市国有资产监督管理委员会。 4、主营装卸及综合物流、商品销售等,重庆处在"一带一路"、长江经济带等重大发展战略的节点上,承东 启西、连接南北,是衔接和联动几大战略的重要枢纽,具有良好的互联互通基础。 该股筹码平均 ...

Core Viewpoint - 弘业期货 is experiencing a decline in stock performance, with a recent drop of 0.20% and a total market capitalization of 10.269 billion yuan [1] Company Overview - 弘业期货股份有限公司 primarily engages in commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, fund sales, and financial asset investment [2][7] - The company is the first A+H share listed company in the futures industry and is controlled by the Jiangsu Provincial Government State-owned Assets Supervision and Administration Commission [3][7] Financial Performance - For the period from January to September 2025, 弘业期货 reported zero operating income and a net profit attributable to shareholders of 2.0897 million yuan, a year-on-year decrease of 87.27% [7] - Cumulative cash dividends since the A-share listing amount to 44.3422 million yuan [8] Shareholder Structure - As of September 30, 2025, the number of shareholders is 54,400, a decrease of 13.10% from the previous period [7] - Major shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable reductions in their holdings [8] Market Activity - The stock has seen a net outflow of 1.308 million yuan today, with a continuous reduction in main funds over the past three days [4][5] - The average trading cost of the stock is 11.58 yuan, with the current price near a support level of 9.93 yuan [6]

Core Viewpoint - The A-share market continues to decline, with major indices experiencing losses, while the traditional Chinese medicine (TCM) ETFs show resilience and growth amid a recovering market sentiment in the TCM sector [1][2]. Market Performance - The Shanghai Composite Index fell by 0.51% to 3878 points, the Shenzhen Component Index dropped by 0.78%, and the ChiNext Index decreased by 1.12% [1]. - The total market turnover reached 1.68 trillion yuan, an increase of 763 billion yuan compared to the previous trading day, with over 3800 stocks declining [1]. TCM ETFs - TCM ETFs, including the TCM ETF, TCM ETF Huatai-PB, and TCM 50 ETF, experienced gains, with respective increases of 0.92%, 0.90%, and 0.81% [2]. - The TCM ETF tracks the CSI Traditional Chinese Medicine Index, with key stocks including Yunnan Baiyao, Pien Tze Huang, and Tong Ren Tang [1][2]. TCM Market Trends - The TCM market is showing signs of recovery, with increased market activity and positive investment sentiment [2]. - The TCM sector benefits from both pharmaceutical and consumer attributes, with a high dividend yield of 2.69% over the past 12 months, placing it in the 90.91% historical percentile since its inception [2]. Price Governance in TCM - Multiple regions in China have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive drug market [3][4]. - The focus is on high-priced TCM products with significant clinical usage, particularly those sold primarily in the outpatient market [4]. Industry Dynamics - The ongoing price governance and centralized procurement are expected to lead to price convergence between hospital and outpatient markets, reshaping competitive factors in the industry [4]. - Companies with unique products, strong clinical value, and effective cost control are likely to gain competitive advantages [4]. Investment Themes - Three main investment themes are identified: 1. Price governance, focusing on price reductions and market share for competitive products [5]. 2. Consumption recovery, driven by macroeconomic improvement and aging population, benefiting TCM sales [6]. 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [6]. Recommended Investment Targets - Companies with strong R&D capabilities, unique products, and those less affected by centralized procurement are recommended for investment [6]. - Emphasis is placed on TCM brands with strong market presence and those benefiting from state-owned enterprise reforms [6].